Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections
Alexandro Rodríguez-Rojas, María D. Maciá, Alejandro Couce et al. · 2010
Read Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections by Alexandro Rodríguez-Rojas, María D. Maciá, Alejandro Couce et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0010193.txt.
Description
The authors were Alexandro Rodríguez-Rojas, María Maciá, Alejandro Couce, and others. Their 2010 PLOS ONE study looked at drug resistance in a tough germ. The drug fosfomycin treats simple bladder and gut infections well. Mutants that resist it arise often in lab tests, but they were thought to pay a high cost for that trait.
The team checked how resistance emerges and what it costs in living hosts. Their concern was plain: if there is no cost in the body, resistant germs can persist. That would weaken a useful drug against infections caused by Pseudomonas aeruginosa.
Catalog record
| CREATOR | Alexandro Rodríguez-Rojas, María D. Maciá, Alejandro Couce et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010193